TY - JOUR
T1 - Frequency of anticancer drug use at the end of life :
T2 - a scoping review
AU - Szigethy, Endre
AU - Dorantes, Rosario
AU - Sugrañes, Miguel
AU - Madera, Meisser
AU - Solà, Ivan
AU - Urrútia, Gerard
AU - Bonfill, X. (Xavier)
PY - 2023
Y1 - 2023
N2 - Anticancer drug use at the end of life places potential extra burdens on patients and the healthcare system. Previous articles show variability in methods and outcomes; thus, their results are not directly comparable. This scoping review describes the methods and extent of anticancer drug use at end of life. Systematic searches in Medline and Embase were conducted to identify articles reporting anticancer drug use at the end of life. We selected 341 eligible publications, identifying key study features including timing of research, disease status, treatment schedule, treatment type, and treatment characteristics. Among the subset of 69 articles of all cancer types published within the last 5 years, we examined the frequency of anticancer drug use across various end of life periods. This comprehensive description of publications on anticancer drug use at end of life underscores the importance of methodological factors when designing studies and comparing outcomes. The online version contains supplementary material available at 10.1007/s12094-023-03234-1.
AB - Anticancer drug use at the end of life places potential extra burdens on patients and the healthcare system. Previous articles show variability in methods and outcomes; thus, their results are not directly comparable. This scoping review describes the methods and extent of anticancer drug use at end of life. Systematic searches in Medline and Embase were conducted to identify articles reporting anticancer drug use at the end of life. We selected 341 eligible publications, identifying key study features including timing of research, disease status, treatment schedule, treatment type, and treatment characteristics. Among the subset of 69 articles of all cancer types published within the last 5 years, we examined the frequency of anticancer drug use across various end of life periods. This comprehensive description of publications on anticancer drug use at end of life underscores the importance of methodological factors when designing studies and comparing outcomes. The online version contains supplementary material available at 10.1007/s12094-023-03234-1.
KW - Neoplasms
KW - Anticancer agents
KW - Terminal care
KW - Medical overuse
U2 - 10.1007/s12094-023-03234-1
DO - 10.1007/s12094-023-03234-1
M3 - Article
C2 - 37286888
SN - 1699-3055
SP - 1
EP - 12
JO - Clinical & Translational Oncology
JF - Clinical & Translational Oncology
ER -